British health officials on Wednesday (September 28) warned that increased circulation of flu and a resurgence in Covid-19 could lead to a difficult winter that
increases pressure on the already stretched NHS.
Warnings over a possible "twindemic" of Covid-19 and flu have been issued each winter since the start of the coronavirus pandemic in early 2020, but Covid
restrictions that limited social contact have meant flu levels stayed low.
However, the government ended coronavirus restrictions earlier this year, meaning that social contact rates have returned to near pre-pandemic norms while immunity
to flu is relatively low.
The UK Health Security Agency (UKHSA) said that given the risk it was important those eligible took up vaccines against Covid and flu.
"There are strong indications we could be facing the threat of widely circulating flu, lower levels of natural immunity due to less exposure over the last three
winters and an increase in Covid-19 circulating," said Susan Hopkins, chief medical advisor at UKHSA.
Calls have been made for more pharmacies to help with the rollout of the county's coronavirus booster jabs.
Around 25 pharmacies in Kent and Medway have been distributing vaccines to thousands of patients.
This represents just seven per cent of the 320 pharmacies in the county.
The call comes despite staff shortages and growing workload pressures, such as carrying out non-essential tasks, which include patient satisfaction surveys.
Shilpa Shah, the chief executive officer at the Kent Local Pharmaceutical Committee, said: "We have workforce issues, but are pulling together to deliver essential patient services and Covid vaccinations at the same time."
Pharmacies are one of several health organisations working hard to ensure that everyone aged 18 and over will be offered a booster vaccination by the target of January 31, which has been set by the government.
Daily hospital admissions in Britain could soon hit a new high because the Omicron variant of the coronavirus is spreading so fast, piling pressure on a health service struggling with staff sickness, England's chief medical officer said on Thursday (December 16).
Britain recorded on Wednesday its highest number of daily coronavirus cases since the start of the pandemic at 78,610.
Omicron is so transmissible that even if it proves to be milder than other variants, it could still cause a surge in hospital admissions, Chris Whitty told lawmakers.
The record for the number of people admitted to hospital with Covid-19 is 4,583 set in January.
"It is possible, because this is going to be very concentrated over a short period of time, even if it's milder, you could end up with a higher number than that going into hospital on a single day," he said.
Britain has approved a new coronavirus vaccine by the Austrian-French drugmaker Valneva.
"An approval has been granted after the Valneva Covid-19 vaccine was found to meet the required safety, quality and effectiveness standards," the Medicines and
Healthcare products Regulatory Agency said in a statement on Thursday (April 14), adding: "It is also the first, whole-virus inactivated Covid-19 vaccine to gain
regulatory approval in the UK."
In vaccines such as Valneva's VLA2001, the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response. It is seen by some as having the potential to win over people wary of some which use new mRNA technology.
Valneva CEO Thomas Lingelbach said that "this authorisation could pave the way for the availability of an alternative vaccine solution for the UK population."
Homecare.co.uk's famed Top 20 UK awards have turned out a multiple winner, with Blue Angel Care a highlight.
Blue Angel Care took two prestigious gongs , Top 20 Homecare Group Provider in the UK and Top 20 Home Care Providers in South East England.
Finding innovative ways to circumnavigate the difficulties of the coronavirus pandemic, the homecare specialists have grown to a nationwide team of more than 200
care givers.
Dariusz Motka, Managing Director and Co-Founder of Blue Angel Care, said in a statement: "We are eternally grateful to the readers and reviewers of Homecare.co.uk
for honouring us with, not one, but two awards."
Praising his staff, Dariusz added : "More so, we are all grateful to the incredibly hardworking and professional staff that help to train so many capable carers
every single week."
Britain has started counting possible Covid-19 reinfections in its daily coronavirus data, changing its approach to reflect the increased number of people
catching the disease for a second time as the Omicron variant predominates.
The UK Health Security Agency (UKHSA) added around 840,000 cases to the cumulative total, taking it to 17.3 million coronavirus infections reported.
Britain's daily Covid statistics previously would only count people who had tested positive for the first time to avoid double-counting people who had received multiple positive test results for the same infection.
However, with variants such as Omicron leading to an increase in reinfections, the UKHSA said it would change its method to treat positive tests as separate infections if there was at least 90 days between test results. The change took effect on Monday (January 31).
"Reinfection remained at very low levels until the start of the Omicron wave. It is right that our daily reporting processes reflect how the virus has changed," said Steven Riley, UKHSA's Director General of Data and Analytics.
Former chancellor Rishi Sunak, one of two candidates vying to be Britain's next premier, criticised the way outgoing prime minister Boris Johnson handled the
Covid-19 pandemic, saying it had been a mistake to "empower" scientists and that the downsides of lockdowns were suppressed.
The Tories are choosing a new leader after Johnson was forced to quit when dozens of ministers resigned in protest at a series of scandals and missteps. Party members
are voting to select either Sunak or foreign secretary Liz Truss, who will take over next month.
Opinion polls show Sunak is behind in race. The handling of the pandemic has become an issue, with Truss saying this month she would never again approve another
lockdown and also asserting that as trade minister at the time she was not involved in taking the key decisions about how to respond.
Sunak said the government had been "wrong to scare people" about coronavirus. He said he was banned by officials in Johnson's office from discussing the "trade-offs"
of imposing coronavirus-related restrictions, such as the impact on missed doctor's appointments and lengthening waiting lists for healthcare in the NHS.
Around 90 percent of coronavirus patients in intensive care units have not had a booster jab, prime minister Boris Johnson said on Wednesday (December 29) - defending his decision not to tighten virus curbs in England.
Speaking at a vaccination centre, Johnson urged people to get "vital" booster jabs, saying "the overwhelming majority" of those currently going into intensive care in our hospitals have not had the booster jab.
"I've talked to doctors who say the numbers are running up to 90 percent of people in intensive care who are not boosted," the prime minister added in Milton Keynes in Hertfordshire.
Those who have not been vaccinated are "eight times more likely to get into hospital," he warned.
The UK has been hit by a huge surge of the new Omicron variant, with England and Wales reporting record case numbers on Tuesday. The UK has been one of Europe's worst hit with a death toll of 148,021.
The UK Health Security Agency on Friday said it had designated a sub-lineage of the dominant and highly transmissible Omicron coronavirus variant as a variant under investigation.
BA.2, which does not have the specific mutation seen with Omicron that can be used as a proxy to easily distinguish it from Delta, is being investigated but has not been designated a variant of concern.
"It is the nature of viruses to evolve and mutate, so it's to be expected that we will continue to see new variants emerge," Dr Meera Chand, incident director at the UKHSA, said.
"Our continued genomic surveillance allows us to detect them and assess whether they are significant."
Britain had identified 53 sequences of the BA.2 sub-lineage as of January 10, with updated figures due to be published later on Friday.
The British scientist who led the research underpinning AstraZeneca's coronavirus vaccine said at the weekend that a new jab could be developed against the emerging Omicron variant "very rapidly" if needed.
Professor Andrew Pollard, director of the Oxford Vaccine Group, also said existing vaccines should work against the new strain, but that would only become apparent
after more research in the coming weeks.
"It's extremely unlikely that a reboot of a pandemic in a vaccinated population like we saw last year (with the Delta variant) is going to happen," he told BBC radio.
But if required, "The processes of how one goes about developing a new vaccine are increasingly well-oiled, so if it's needed that is something that could be moved very rapidly."
In a statement, AstraZeneca said it had "developed, in close collaboration with Oxford University, a vaccine platform that enables us to respond quickly to new variants that may emerge".
British drugmaker GSK said on Tuesday (December 7) its antibody-based Covid-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.
The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.
Last week, another pre-clinical data showed that the drug had worked against key mutations of the Omicron variant. Sotrovimab is designed to latch on to the spike
protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein.
"These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO," GSK chief scientific officer Hal Barron said.
England is set to reopen temporary field hospitals to contain a possible overspill of inpatients due to a surge in coronavirus cases, the national health service said Thursday.
Fuelled by the highly contagious Omicron variant, daily cases have ballooned, standing at more than 183,000 on Wednesday.
NHS England said it would start building the structures in the grounds of eight hospitals in cities including London, Bristol and Leeds from this week, with each
designed to house around 100 extra patients.
"Given the high level of Covid-19 infections and increasing hospital admissions, the NHS is now on a war footing," National medical director Stephen Powis said.
The extra beds are designed for patients who are recovering from illnesses, including those who no longer have Covid, to free up space and staff to treat large numbers of virus cases.
Britain will offer a Covid-19 booster shot to all adults and could halve the dose interval for booster jabs from six to three months in a bid to accelerate its vaccination programme amid concern over the new Omicron coronavirus variant, as number of new cases found in the country rise.
The move, backed by a scientific advisory body and Health Secretary Sajid Javid, comes as ministers scramble to react swiftly to the new variant, which was first detected in South Africa.
Prime minister Boris Johnson has responded to the emergence of Omicron by making mask-wearing compulsory in shops and on public transport in England.
Until now, only adults in the UK aged 40 and above were eligible for a booster dose six months after their last.
But that timeframe will now be halved to three months, alongside the programme's expansion to all over-18s, with priority given to older people.
"These measures will protect more people, more quickly and make us better protected as a nation," Javid told MPs.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a second "bivalent" vaccine as a Covid-19 booster.
The updated booster vaccine made by Pfizer/BioNTech, targeting two coronavirus variants, has been approved for use in individuals aged 12 years and above.
In each dose of the booster vaccine, 'Comirnaty bivalent Original/Omicron', half of the vaccine (15 micrograms) targets the original virus strain and the other
half (15 micrograms) targets Omicron (BA.1).
Dr June Raine, MHRA chief executive said: "I am pleased to announce that we now have a second approved vaccine for the UK Autumn booster programme. The clinical
trial of the Pfizer/BioNTech bivalent vaccine showed a strong immune response against the Omicron BA.1 variant as well as the original strain.
Bivalent vaccines are helping us to meet the challenge of an ever-evolving virus, to help protect people against Covid-19 variants. We have in place a comprehensive
safety surveillance strategy for all UK-approved Covid-19 vaccines, and this will include the updated booster we approved today."
There is no sign of a surge of the Omicron coronavirus variant in Britain so far, the chief of the UK Health Security Agency said on Tuesday, adding that there was no rise in the proportion of tests with a quirk that distinguishes it from Delta.
Jenny Harries said there were five confirmed Omicron cases in England and 10 "highly likely" cases, but that was not a sign of an increase in "S-gene target failure" in PCR tests in Britain, which is a feature of Omicron.
"Right across the country we watch for… S-gene target failure, which is a sort of proxy measure," Harries told BBC radio. Cases with S-gene target failure can then be prioritised for full genomic sequencing.
The prevalence of Covid-19 infections in England rose to around one in 60 people in the week ending November 27, the Office for National Statistics said today (December 03), led higher by the dominant Delta variant rather than the newly identified Omicron.
The prevalence was up from one in 65 reported the previous week, the ONS said, adding that 99 per cent of all coronavirus infections which were sequenced were
genetically compatible with the Delta variant.
"To date, we have not identified any infections compatible with the new Omicron variant (B.1.1.529) among our survey participants," the ONS said.
Prime Minister Boris Johnson has introduced travel restrictions and some mask mandates, with a view to slowing the spread of Omicron while work is undertaken to
understand it better.
There have been 42 confirmed cases of the variant in Britain, which has mutations consistent with reduced vaccine efficacy.
Britain's Covid booster campaign is set to kick off this September, after the country became the first in the world to approve an Omicron-adapted shot.
Around 26 million people in Britain are estimated to be eligible for an autumn Covid-19 booster, having had at least two Covid vaccine doses already, a UK Health
Security Agency (UKHSA) spokesperson said.
The preference is to deploy what is known as a "bivalent vaccine" that targets both the original virus and the Omicron variant through the autumn campaign, but that
will depend on the health regulator (MHRA) approving such shots and the state of vaccine supplies.
The UK's Joint Committee on Vaccination and Immunisation (JCVI) has advised boosters should be given to over-50s, individuals in clinical risk groups, frontline
workers and care-home staff ahead of the winter, when respiratory viruses are typically at their peak.
On Monday (August 15), the MHRA gave Moderna's bivalent shot conditional approval.
The endorsement of the vaccine is based on data that showed it produced a marginally better immune response against some Omicron variants, versus the original novel
coronavirus - although whether that translates into stronger protection against serious disease is unclear.
The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter.
The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2).
UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University,
analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023.
Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader
community. The sample will be structured to broadly reflect key population characteristics.
The Omicron variant of coronavirus is less likely to cause long Covid than previous variants, according to the first peer-reviewed study of its kind from the UK.
Researchers at King's College London, using data from nearly 100,000 people who logged their Covid symptoms via an app, found the odds of developing long Covid
after infection were 20 per cent to 50 per cent lower during the Omicron wave in the UK compared to Delta. The figure varied depending on the patient's age and the
timing of their last vaccination.
Long Covid, which includes prolonged symptoms ranging from fatigue to 'brain fog', can be debilitating and continue for weeks or months. It is increasingly being
recognised as a public health problem, and researchers have been racing to find out if Omicron presents as big a risk of long Covid as previously dominant variants.
The study from King's is believed to be the first academic research to show Omicron does not present as great a risk of long Covid, but that does not mean long
Covid patient numbers are dropping, the team said.
While the risk of long Covid was lower during Omicron, more people were infected, so the absolute number now suffering is higher.
"It's good news, but please don't decommission any of your long Covid services," lead researcher Dr Claire Steves said, appealing to health-service providers.
Prime minister Boris Johnson received his Covid-19 booster shot on Thursday (December 2) and urged others to follow suit to help the country fend off the Omicron variant of coronavirus.
Wearing a mask, Johnson briefly chatted to staff and others queuing for their shots at the vaccination centre in central London, asking them if they were there to receive a booster dose and thanking them for attending.
Johnson, who said it could "have gone either way" when he was treated in hospital for Covid last year, was later filmed rolling up his shirt sleeve and receiving his shot.
"Fantastic. Thank you so much," he said to the nurse, before receiving a badge that said "I've boosted my immunity".